RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits im

Michael Schmitt, Anita Schmitt, Markus T. Rojewski, Jinfei Chen, Krzysztof Giannopoulos, Fei Fei, Yingzhe Yu, Marlies Götz, Marta Heyduk, Gerd Ritter, Daniel E. Speiser, Sacha Gnjatic, Philippe Guillaume, Mark Ringhoffer, Richard F. Schlenk, Peter Liebisch, Donald Bunjes, Hiroshi Shiku, Hartmut Dohner, and Jochen Greiner Department of Internal Medicine III, University of Ulm, Robert-Koch-Str. 8, 89081 Ulm, Germany; Institute for Transfusion Medicine, University of Ulm and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm gemeinnützige GmbH, Helmholtzstr. 10, 89081 Ulm, Germany; Lublin Medical University, Dept. of Clinical Immunology, Raclawickie 1, 20-950 Lublin, Poland; Ludwig Institute for Cancer Research (LICR) New York Branch, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY10021, USA; Division of Clinical Onco-Immunology, LICR, Hôpital Orthopédique, Niveau 5 Est, Av. Pierre-Decker 4, CH-1005 Lausanne, Switzerland; LICR, Lausanne Branch, University of Lausanne, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland; Mie University Medical School, 2-174 Edo-bashi, 514 Tsu, Japan;